Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on January 26, 2021. The filing relates to the issuance of a preliminary prospectus supplement for an underwritten public offering of common stock. The financial data referenced pertains to the period ended December 31, 2020.
Key Financial Metrics
- Cash, Cash Equivalents, and Investments: Approximately $81.9 million as of December 31, 2020.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, or operating margins.
- Debt and Liquidity: No specific debt figures are disclosed in this report; liquidity is represented by the cash balance noted above.
Material Changes and Unusual Items
The primary event reported is the initiation of an underwritten public offering. The financial figures provided are preliminary and unaudited. The Company explicitly states that these numbers are subject to change pending the completion of audited consolidated financial statements for the year ended December 31, 2020. No comparative data for the prior period is included in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The Company expects to complete its audited financial statements subsequent to the completion of the Offering.
Risks and Contingencies: There is a risk that the Company or its independent registered public accounting firm may identify items requiring adjustments to the preliminary estimated cash balance, which could be material. The information in Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and investments balance once the 2020 annual report is filed.
- Confirm the final terms and proceeds of the underwritten public offering announced in the press release (Exhibit 99.1).
- Review the full preliminary prospectus supplement for detailed use of proceeds and risk factors not summarized in this 8-K.
- Note the discrepancy between the request metadata (Gyre Therapeutics) and the filing registrant (Catalyst Biosciences).